R&D News | pharmaphorum

News

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phas

News

Pilot study finds VR training benefit in depression

People with depression can sometimes have impaired memory, particularly for positive events, which can contribute to cognitive problems and impair their daily lives.

News

Agomab raises $100m for Crohn’s drug, and other financings

Agomab Therapeutics has closed a $100 million third-round financing, heading a list of recent funding rounds that also features AstronauTx, MinervaX, Precede Bio and Limma

News

Almirall signs $210m bispecifics deal with EpimAb

A few months after raising €200 million in investment capital to boost its pipeline, Spanish drugmaker Almirall has used some of the cash for a bispecific antibody partner

News

MHRA pledges two-week review for low-risk clinical trials

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has implemented one part of its plan to reform the regulations governing clinical trials, namely an ini

News

Incyte’s oral vitiligo drug heading for phase 3

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in pati

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

Pilot study finds VR training benefit in depression

Agomab raises $100m for Crohn’s drug, and other financings

Almirall signs $210m bispecifics deal with EpimAb

MHRA pledges two-week review for low-risk clinical trials

Incyte’s oral vitiligo drug heading for phase 3

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks